NCT06392672|Completed
Evaluation of the Effect of Drug-Related Problems in Pulmonary Embolism
Evaluation of the Effect of Management of Drug-Related Problems on Clinical Outcomes of Pulmonary Embolism Outpatients
Loading search results
Evaluation of the Effect of Management of Drug-Related Problems on Clinical Outcomes of Pulmonary Embolism Outpatients
Sponsor study identifier
interventional
50
1 country
1
Study Start
January 15, 2022
Actual (reported)Primary Completion
January 15, 2023
Actual (reported)Study Completion
January 15, 2023
Actual (reported)Pulmonary embolism (PE) presents notable risks of morbidity and mortality, underscoring the need for customized anticoagulant treatment. There is a scarcity of research examining drug-related issues (DRPs) in PE. This research endeavor seeks to assess how addressing DRPs affects the clinical outcomes of PE patients receiving outpatient care, offering valuable insights to bolster patient safety measures. This study will conduct a randomized controlled trial on PE patients in Istanbul, Turkey, from January 15, 2022, to January 15, 2023. The intervention group (IG) will receive clinical pharmacist (CP) recommendations for DRPs, while the control group (CG) will undergo observation only. Evaluations will occur at 90- and 180-days post-discharge, focusing on DRPs, CP interventions, and patient outcomes. Data will be systematically recorded and analyzed, adhering to ethical standards and employing the PCNE v9.1 classification system.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 15, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 15, 2022
Actual (reported)January 15, 2023
Actual (reported)January 15, 2023
Actual (reported)April 25, 2024
Actual (reported)April 30, 2024
Actual (reported)Acceptance rate of suggested intervention (number)
Acceptance rate of suggested intervention. Dru-related problems and recommendations are classified according to PCNE (Pharmaceutical Care Network Europe) version 9.1. It was recorded how many suggestions were made in the intervention group and how many of these suggestions were accepted.
From the date of randomization until there are 50 patient participants in each group. Average 1 year.
Bleeding
Occasions of bleeding within the 180th day.
From the date of randomization until there are 50 patient participants in each group. Average 1 year.
Increase in pulmonary embolism related quality of life
From the date of randomization until there are 50 patient participants in each group. Average 1 year.
Group: Group in which only observation is made by the clinical pharmacist For patients in this group, no intervention (i.e. recommendation) will be made to physicians by the clinical pharmacist. Within the intervention group, patient characteristics such as the underlying conditions, and the appropriateness of prescribed medications were evaluated for the patients who received treatment for pulmonary embolism and met the inclusion criteria. The participant will take standard treatment. Evaluations will be recorded.
Intervention Group: Group to which the clinical pharmacist makes recommendations For patients in this group, intervention (i.e. recommendation) will be made to physician in charge by the clinical pharmacist. Within the intervention group, patient characteristics such as the underlying conditions, and the appropriateness of prescribed medications were evaluated for the patients who received treatment for pulmonary embolism and met the inclusion criteria. Through medication reviews, evaluations were made to identify drug-related problems and provide solutions to these problems. The clinical pharmacist provided recommendations to the physicians regarding significant clinically important problems.
The drugs administered to patients during scheduled hospital visits will be recorded. A detailed medication review will be conducted by the clinical pharmacist. As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Bezmialem Vakif University
Istanbul, 34093, Turkey (Türkiye)
50 participants (actual enrollment reported by the registry).
First Submitted
April 25, 2024
First Posted
April 30, 2024
Study Start
January 15, 2022
Actual (reported)Venous Phase Dual Energy CT in Patients Suspected for Pulmonary Embolism.
Contact the study team to confirm eligibility.
Primary Completion
January 15, 2023
Actual (reported)Study Completion
January 15, 2023
Actual (reported)Last Updated
April 30, 2024
Record last verified: 2024-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: